Circulating Angiogenesis Factors in Patients with Non-Hodgkin’s Lymphoma
| Autor: | N. Abdel-Bary, R. F. Sadek, R. M. Talaat, A. M. Abdel-Aziz, E. A. El-Maadawy |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
Vincristine Chemotherapy medicine.medical_specialty Environmental Engineering Platelet-derived growth factor Cyclophosphamide business.industry medicine.medical_treatment CHOP medicine.disease Industrial and Manufacturing Engineering Lymphoma Non-Hodgkin's lymphoma Vascular endothelial growth factor chemistry.chemical_compound Endocrinology chemistry hemic and lymphatic diseases Internal medicine medicine business medicine.drug |
| Zdroj: | British Journal of Medicine and Medical Research. 4:3366-3383 |
| ISSN: | 2231-0614 |
| DOI: | 10.9734/bjmmr/2014/8582 |
| Popis: | Aims: Non-Hodgkin’s lymphoma (NHL) is a heterogeneous group of hematological malignancies. Several angiogenic factors are important in NHL. The objective of this study was to determine plasma levels of various proangiogenic [vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), tumor necrosis factor (TNFα), transforming growth factor (TGF-β), interleukin (IL-6), IL-8] and antiangiogenic [IL-4, IL-12, interferon gamma (IFN-)] factors in NHL patients and implication of CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone) therapy on these mediators. Study Design: This study was conducted on 100NHL patients recruited from the Oncology Hospital, Menofia University, Egypt. Fifty patients had different doses of CHOP chemotherapy and 50 patients were without treatment. Another 119 healthy blood donors were served as healthy controls. Methodology: Enzyme-linked immunosorbent assay (ELISA) was used to detect the concentrations of these mediators in plasma of NHL patients and normal controls. Results: Several proangiogenic (VEGF, PDGF, IL-8, and TNF-α) (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|